Analysts expect Nanoviricides, Inc. to report revenue of 0.00 for Q4 26, against a range of 0.00 to 0.00.
| Metric | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.88 M | 21.13 M | 22.98 M | |||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.54 M | 19.10 M | 20.11 M | |||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.71 M | 20.12 M | 21.55 M |
Analysts expect Nanoviricides, Inc. to report earnings per share of -0.30 for Q4 24, against a range of -0.31 to -0.29. The most recent reported quarter, Q3 26, came in at -0.10, a 25.0% miss against the -0.08 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | - | -0.12 | -0.09 | -0.11 | -0.10 | - | - | - | - | |||||||||||||
| High Estimate | -0.29 | -0.15 | -0.18 | -0.18 | -0.18 | -0.16 | -0.09 | -0.08 | -0.09 | -0.09 | -0.09 | -0.10 | |||||||||||||
| Low Estimate | -0.31 | -0.17 | -0.20 | -0.22 | -0.20 | -0.18 | -0.11 | -0.08 | -0.11 | -0.11 | -0.09 | -0.12 | |||||||||||||
| Consensus Estimate | -0.30 | -0.16 | -0.19 | -0.20 | -0.19 | -0.17 | -0.10 | -0.08 | -0.10 | -0.10 | -0.09 | -0.11 |